Leqvio market report points to aging population and North America lead

The Business Research Company says the Leqvio market is expanding on stronger LDL-cholesterol management, RNA interference advances and rising cardiovascular risk reduction efforts. North America leads the market now, while Asia-Pacific is projected to grow fastest through 2026.

Why it matters: - Leqvio’s market growth tracks a broader shift toward long-interval cardiovascular therapies that can help reduce LDL cholesterol in high-risk patients. - The report links demand to aging populations, rising preventive cardiology use and adoption of RNA-based medicines. - North America’s current lead and Asia-Pacific’s faster expected growth point to uneven regional opportunities for drug makers and investors.

What happened: - The Business Research Company published its Leqvio Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Leqvio market is changing through 2026 as medical technology advances and demographic patterns shift. - The company offers a free sample of the report and the full market report.

The details: - Leqvio uses an siRNA-based mechanism that targets PCSK9 mRNA in the liver. - That mechanism helps the liver clear LDL cholesterol more effectively. - Lower LDL cholesterol reduces the risk of heart attacks, strokes and other cardiovascular complications in high-risk patients. - The report ties market growth to advances in RNA interference technology, growth in cardiovascular specialty clinics and better injectable drug delivery systems. - The report also cites improved awareness of LDL cholesterol management, novel RNA therapeutics, cardiometabolic research and long-interval dosing therapies as growth drivers. - The report says Leqvio’s sustained effect supports durable lipid-lowering treatment for patients and clinicians. - The aging population is a major demand driver because older adults face higher cardiovascular risk and need simpler treatment regimens. - A January 2024 Population Reference Bureau projection says the U.S. population age 65 and older will rise from 58 million in 2022 to 82 million by 2050. - That projection would lift the 65-plus share of the U.S. population from 17% to 23%. - North America holds the largest Leqvio market share as of 2025. - Asia-Pacific is forecast to post the fastest growth over the coming years. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The report positions Leqvio as part of a larger preventive-cardiology push rather than a narrow drug-specific story. - Long-interval dosing is a commercial advantage because it can improve adherence, especially in older patients and other high-risk groups. - Regional growth patterns suggest mature markets will still drive revenue, but emerging healthcare investment in Asia-Pacific may reshape the market mix.

What's next: - The market outlook through 2026 will likely depend on how quickly RNA therapeutics gain broader clinical acceptance. - Adoption will also hinge on whether healthcare systems keep prioritizing cardiovascular risk reduction and adherence-friendly therapies. - The Business Research Company says its updated report set will continue adding forecasting tools and trend analysis for 2026 research buyers.